Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(37)
•••
Comment by PlaySafeon Aug 12, 2021 2:14pm
137 Views
Post# 33695021

RE:RE:RE:Time

RE:RE:RE:TimeI agree that that the science needs to be there for the trial to work and we don't know yet if the drug is powerful enough at the lower dosage to work that is why they are re-doing the Phase 2 trial.  The other big component and uncertainty in a trial is the human component.  The participants are asked to evalute the effectiveness of the drug and if tthere is not a statistical significance from the drug vs the placebo group then game over.  So  I'm not sure you understand how the Phase 2 trial works and what the risks are.  To complicate things further, NSAIDs are typically compared/evaluated on their WOMAC scores so even if the new Phase 2 is successful but the WOMAC scores do not compare with NSAIDs that are currently on the market then this will also impact investor centiment. But stick to the belief that they can control statistical significance.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities